Kaiyuan Securities: The pharmaceutical industry is gradually transitioning from old to new growth drivers, with innovation leading to breakthroughs across multiple fronts.

Chemical pharmaceuticals and biologics: Differentiated pipelines continue to emerge, overseas expansion is accelerating, and collaboration models are becoming increasingly diverse, driving sustained growth in the innovative drug industry.

Zhitong FinanceMay 22 10:15

Bide Pharmaceutical (688073.SH): Shareholders Xinxi Management, Landan Management, and their acting-in-concert parties plan to collectively reduce their shares by no more than 3%.

Gelonghui, May 18th: Bide Pharmaceutical (688073.SH) announced that due to the liquidity needs of its shareholders, Xinxigu Management, Landan Management, and their concerted actor Mr. Wu Bo plan to reduce their shares in the company through centralized bidding or block trading within three months after 15 trading days from the disclosure of this reduction plan, depending on market conditions. Specifically, Xinxigu Management plans to reduce no more than 908,800 shares via block trading, which does not exceed 1.00% of the company's total share capital, and no more than 454,400 shares via centralized bidding, which does not exceed the company’s...

Gelonghui FinanceMay 18 19:22

Bide Pharmaceutical (688073) 2025 Annual Report and 2026 Q1 Report Commentary: Revenue Remains Steady While Profit Grows Rapidly

Company Announcement: In 2025, the company achieved operating revenue of 1.324 billion yuan, representing a year-on-year increase of 20.13%. Net profit attributable to shareholders reached 152 million yuan, marking a year-on-year increase of 29.22%, while net profit attributable to shareholders after deducting non-recurring items amounted to 132 million yuan.

Western SecuritiesMay 11 00:00

Bide Pharmaceutical (688073): Q1 2026 Earnings Exceed Expectations with Steady Improvement in Profitability

2026 Q1 performance exceeded expectations, with profitability steadily improving. The 'Buy' rating is maintained. In 2026 Q1, the company achieved revenue of 323 million yuan (+9.08%) and a net profit attributable to shareholders of 47 million yuan (+52.5%).

Open Source SecuritiesMay 7 11:06

Bide Pharmaceutical: First Quarter Report for 2026

SZSIApr 30 00:00 · Announcements

First Quarter Report for 2026

SZSIApr 30 00:00 · Announcements